Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 110-123
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.110
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.110
Table 2 Properties of statins
| Statin | Solubility[3]
| Metabolism[3]
| Human dose to lower cholesterol (mg) | ||
| Low | Moderate | High | |||
| Simvastatin | Lipophilic | CYP3A4 | 10 | 20-40 | - |
| Atorvastatin | Lipophilic | CYP3A4/2C9 | - | 10-20 | 40-80 |
| Fluvastatin | Lipophilic | CYP2C9 | 20-40 | 80 | - |
| Pitavastatin | Lipophilic | Non-CYP450 | - | 1-4 | - |
| Lovastatin | Lipophilic | CYP3A4/2C9 | 20 | 40-80 | - |
| Rosuvastatin | Hydrophilic | Non-CYP450 | - | 5-10 | 20-40 |
| Pravastatin | Hydrophilic | Non-CYP450 | 10-20 | 40-80 | - |
- Citation: Uemura N, Hayashi H, Baba H. Statin as a therapeutic agent in gastroenterological cancer. World J Gastrointest Oncol 2022; 14(1): 110-123
- URL: https://www.wjgnet.com/1948-5204/full/v14/i1/110.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.110